CoChat

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study

Open access
Fang, Ton, Al Khleifat, Ahmad, Meurgey, Jacques-Henri, Jones, Ashley, Leigh, P Nigel, Bensimon, Gilbert, Al-Chalabi, Ammar · 2018 · The Lancet Neurology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial. A key question is whether the survival benefit occurs at an early stage of disease, late stage, or is spread throughout the course of the disease. To address this question, we used the King's clinical staging system to do a retrospective analysis of data from the original dose-ranging clinical trial of riluzole. Methods In the original dose-ranging trial, patients were enrolled between December, 1992, and November, 1993, in Belgium, France, Germany, Spain, Canada, the USA, and the UK if they had probable or definite ALS as defined by the El Escorial criteria. The censor date for the riluzole survival data was set as the original study end date of Dec 31, 1994. For this analysis, King's clinical ALS stage was estimated from the electronic case record data of the modified Norris scale, UK Medical Research Council score for muscle strength, El Escorial category, vital capacity, and gastrostomy insertion data. The lowest allocated stage was 2 because the original trial only included patients with probable or definite ALS. We used a χ 2 test to assess the independence of stage at trial enrolment and treatment group, Kaplan-Meier product limit distribution to test the transition from each stage to subsequent stages, and Cox regression to confirm an effect of treatment group on time in stage, controlling for covariates. We did sensitivity analyses by combining treatment groups, using alternative strategies to stage, stratifying by stage at trial enrolment, and using multistate outcome analysis of treatments (MOAT). Findings We analysed the case records of all 959 participants from the original dose-ranging trial, 237 assigned to 50 mg/day riluzole, 236 to 100 mg/day, 244 to 200 mg/day, and 242 to daily placebo. Clinical stage at enrolment did not significantly differ between treatment groups (p=0·22). Time in stage 4 was longer for patients receiving 100 mg/day riluzole than for those receiving placebo (hazard ratio [HR] 0·55, 95% CI 0·36–0·83; log-rank p=0·037). Combining treatment groups and stratifying by stage at enrolment showed a similar result (HR 0·638, 95% CI 0·464–0·878; p=0·006), as did analysis with MOAT where the mean number of days spent in stage 4 was numerically higher for patients given riluzole at higher doses compared with patients receiving placebo. Time from stages 2 or 3 to subsequent stages or death did not differ between riluzole treatment groups and placebo (p=0·83 for stage 2 and 0·88 for stage 3). Interpretation We showed that riluzole prolongs survival in the last clinical stage of ALS; this finding needs to be confirmed in a prospective study, and treatment effects at stage 1 still need to be analysed. The ALS stage at which benefit occurs is important for counselling of patients before starting treatment. Staging should be used in future ALS clinical trials to assess the stage at which survival benefit occurs, and a similar approach could be used for other neurodegenerative diseases. Funding NIHR Maudsley Biomedical Research Centre, The European Union Joint Programme on Neurodegeneration, and the King's Summer Undergraduate Studentship.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(18)30054-1

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Patients progressing from each stage of amyotrophic lateral sclerosis with riluzole or placebo (A) Treatment with 100 mg riluzole per day significantly prolonged time in stage 4 compared with placebo (p=0·037). (B) Treatment with all doses did not prolong time in stage 2 compared with placebo (p=0·827). (C) Treatment with all doses did not prolong time in stage 3 compared with placebo (p=0·882). HR=hazard ratio.
Figure 1 Patients progressing from each stage of amyotrophic lateral sclerosis with riluzole or placebo (A) Treatment with 100 mg riluzole per day significantly prolonged time in stage 4 compared with placebo (p=0·037). (B) Treatment with all doses did not prolong time in stage 2 compared with placebo (p=0·827). (C) Treatment with all doses did not prolong time in stage 3 compared with placebo (p=0·882). HR=hazard ratio.CC BY · PubMed Central
Figure 2 Patients progressing from each stage of amyotrophic lateral sclerosis with 100 mg plus 200 mg riluzole or placebo (A) Treatment with higher doses significantly prolonged time in stage 4 compared with placebo (p=0·006). (B) Treatment with higher doses did not prolong time in stage 2 compared with placebo (p=0·994). (C) Treatment with higher doses did not prolong time in stage 3 compared with placebo (p=0·859). HR=hazard ratio.
Figure 2 Patients progressing from each stage of amyotrophic lateral sclerosis with 100 mg plus 200 mg riluzole or placebo (A) Treatment with higher doses significantly prolonged time in stage 4 compared with placebo (p=0·006). (B) Treatment with higher doses did not prolong time in stage 2 compared with placebo (p=0·994). (C) Treatment with higher doses did not prolong time in stage 3 compared with placebo (p=0·859). HR=hazard ratio.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 259

Metadata

Authors
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A.
Affiliations
  • King's College London (GB)
  • Brighton and Sussex Medical School (GB)
  • Pitié-Salpêtrière Hospital (FR)
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2018-05
Volume
17
Issue
5
Pages
416-422
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2790800342
Cited by
259
References
32
Citations by year
2026: 19 · 2025: 24 · 2024: 39 · 2023: 33 · 2022: 41 · 2021: 33 · 2020: 38 · 2019: 18 · 2018: 13
FWCI
17.18
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • Sussex Research Online (University of Sussex) (submittedVersion, cc-by)
Funders
  • Horizon 2020 Framework Programme (633413)
  • EU Joint Programme – Neurodegenerative Disease Research
  • NIHR Maudsley Biomedical Research Centre
  • Medical Research Council (MR/L501529/1)
  • Economic and Social Research Council (ES/L008238/1)
  • Sanofi
  • National Institute for Health and Care Research
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
  • Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
Keywords
amyotrophic lateral sclerosis, riluzole, disease stage, survival benefit, disease progression, treatment effect heterogeneity, dose-response relationship, mortality reduction, El Escorial criteria, gastrostomy, muscle strength, vital capacity, disease-modifying therapy
MeSH terms
Amyotrophic Lateral Sclerosis, Dose-Response Relationship, Drug, Humans, Retrospective Studies, Severity of Illness Index, Time Factors, Survival Analysis, Outcome Assessment, Health Care, Disease Progression, Excitatory Amino Acid Antagonists, Riluzole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30054-1
The paper
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018). Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30054-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.